GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Other Income (Expense)

CSL (CSLLY) Other Income (Expense) : $1,023 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is CSL Other Income (Expense)?

CSL's other income expense for the CSL's pretax income for the six months ended in Dec. 2023 was $678 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was $1,023 Mil.

CSL Other Income (Expense) Historical Data

The historical data trend for CSL's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Other Income (Expense) Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 404.10 470.10 540.00 624.10 967.00

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 497.60 126.50 622.20 344.80 678.00

CSL Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,023 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL  (OTCPK:CSLLY) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

CSL (CSLLY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Other Income (Expense)
Comparable Companies
ASX:TLX ASX:NEU ASX:IMU ASX:CU6 ASX:CUV ASX:MSB ASX:OPT ASX:IMM ASX:BOT ASX:PYC OCSE:NOVO B VRTX REGN XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX OCSE:GMAB
Traded in Other Exchanges
CMXHF:USA CSJ:Germany CSL:Australia
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
Website
https://www.csl.com
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.